Hair loss treatments are being tested on mice, with methods like minoxidil and stem cell therapy showing promising results. However, human trials are still years away, leading to humorous frustration about mice benefiting first.
User experienced shortness of breath, high blood pressure, red eyes, and eye floaters after using RU58841 for hair loss. They warn others to avoid RU58841 and stick to finasteride, minoxidil, and dutasteride.
The user is experiencing increased hair shedding after using oral minoxidil and is considering topical dutasteride but is concerned about potential worsening. They are also exploring other topical treatments like latanoprost, caffeine, and melatonin, and seeking advice on application methods without pulling out existing hair.
Dutasteride may not effectively stop scalp hair loss and can cause thinning of facial and body hair, including eyebrows. Users suggest considering other causes like autoimmune conditions or vitamin deficiencies and exploring treatments like finasteride or minoxidil.
Clascoterone, an acne treatment that blocks DHT, is being developed for scalp use against hair loss. The conversation also mentions Minoxidil, finasteride, and RU58841 as treatments.
Topical Clascoterone showed a 539% improvement in hair count compared to placebo, but its effectiveness and safety are debated. Users compared it to minoxidil and finasteride, with mixed opinions on its potential release in 2026 or 2027.
The user used finasteride, minoxidil, and ketoconazole for hair loss prevention. After one year, there was no noticeable hair regrowth, but no further hair loss occurred.
Scalp sunburns can cause permanent hair loss, so wearing UPF hats is essential. Tretinoin and Tacrolimus users should be cautious of increased photosensitivity and potential scalp issues.
Promising hair loss treatments in clinical trials include Pyrilutamide, GT20029, CB-03-01, and PP405, with potential market releases between 2027 and 2029. Hair cloning remains experimental and expensive, while existing treatments like finasteride, minoxidil, and microneedling continue to be used.
A woman with AGA is using spironolactone, dutasteride, finasteride, oral minoxidil, bicalutamide, and anti-androgenic birth control but still experiences worsening hair loss. Steroid shots temporarily stop her hair shedding, leading her to question her biopsy results.
The user shared progress on hair regrowth using oral dutasteride, oral minoxidil, and verteporfin procedures. They reported some regrowth after 6-9 months of treatment.
Topical retinol does not affect hair loss and may help hair regrowth. It is different from isotretinoin, which can cause hair loss due to its systemic effects.
The user is using minoxidil and finasteride to treat hair loss and is concerned about shedding and potential aggressive hair loss. They noticed some regrowth in trichoscopy pictures but are unsure about real-life changes.
The conversation discusses how applying topical tretinoin for 5 days can convert 43% of individuals who initially do not respond to minoxidil into responders, enhancing the effect of minoxidil on hair growth. Specific treatments mentioned are minoxidil and tretinoin.
A user's 12 month update on treatment for hair loss, which include oral dutasteride and minoxidil, topical RU88541 and minoxidil, microneedling with hyaluronic acid and FinDuta, experiencing no side effects, positive results and inspiring other users.
The conversation discusses hair loss treatment using finasteride, with the user noting improvements in hair density but a recent decrease in vertex density. Suggestions include adding minoxidil, but the user avoids it due to its toxicity to cats and considers oral minoxidil instead.
The conversation is about a user considering joining a clinical study for Clascoterone (Breezula) after experiencing no results with topical finasteride and minoxidil, and side effects from oral finasteride. The user is seeking advice on clinical study participation and experiences.
Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. Eucapil's effectiveness is questioned due to unconvincing clinical trial and lack of FDA approval.
The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.
Vitamin C mixed with shampoo stopped shedding and promoted hair regrowth after 1.5 years. Both the person and their wife experienced significant hair loss reduction with this method.
Catalase is discussed as a potential treatment for delaying or reversing grey hair, but no reliable medicine currently exists. Other mentioned treatments include Imatinib, senolytics like Quercetin and Fisetin, He Shou Wu, Argan oil, and reishi mushroom extract, though their effectiveness varies.
The user is documenting their hair loss journey, using oral finasteride since January 2025, and plans to add microneedling and rosemary oil. They have experienced no further hair loss but no gains, and are considering oral minoxidil due to having pets.
The user started using Minoxidil and Dutasteride in December 2025 for hair loss. They have noticed improvements according to friends and family but are seeking additional tips to enhance results.
GHK-Cu is discussed for hair loss treatment, with some users reporting positive results using a 4% topical serum, but concerns exist about the long-term safety of oral or injectable forms. The original poster also uses finasteride and plans to start dutasteride.
Exploring hair loss treatments beyond DHT, including Minoxidil, pyruvate, Gt20029 targeting androgen receptors, and vasodilators. Other options like Kx826, adenosine signaling, growth factor topicals, and microneedling are also discussed.
The conversation discusses the hair loss treatment Breezula by Cassiopea, which had a successful Phase II trial and is expected to start Phase III by the end of the year. Users are curious about the timeline for availability and note that it performs slightly better than finasteride at 6 months, slightly worse at 12 months, with the benefit of having no side effects.